Preparedness is real when capability is practised.
Emergency countermeasure development, with the workforce built in parallel. Pandemithon compresses a multidisciplinary vaccine development programme into linked, time-bound, hands-on campaigns. Teams move from regional outbreak evidence to computational design, laboratory production, analytical testing and a structured decision on advancing a candidate countermeasure, and the country keeps the people, the methods and the evidence.
- Bamako, Mali
- Freetown, Sierra Leone
- Accra, Ghana
- Anambra State, Nigeria
- New Jersey, USA
- 10
- Evidence gates, 0 through 9
- 32
- Weeks, sequence to clinical batch
- 2
- Tracks, online and supervised
- 1
- Cohort of national talent
One action. Two outcomes.
Most preparedness funding buys either training or product. Pandemithon is structured so that the same spend produces both, because the training is the development work.
Capacity building
- Multidisciplinary cohort: researchers, clinicians, data scientists, students, press, entrepreneurs
- Instruction in AdCEV vector and fertilised-egg production
- Hands-on practice in harvesting and processing
- Structural genetics bioinformatics for antigen target selection
- Cross-border institutional network building
- Trained personnel prepared for ongoing manufacturing roles
Real countermeasure development
- Active vaccine antigen development on the AdCEV/egg platform
- Inoculation of embryonated eggs with subunit and epitope-display constructs
- Harvesting and characterisation of allantoic fluid
- Yield and expression data documented for regulatory pre-engagement
- Preliminary proof-of-concept dataset for the candidate
- A traceable candidate with a credible route to controlled manufacture
From sequence to clinical-trial batch
Ten gates. Teams advance only when predefined scientific, quality, ethical and programme evidence is accepted by an independent review panel.
- 0Define
- 1Sequences
- 2Design
- 3Build
- 4Express
- 5Immunogenicity
- 6Select
- 7Translate
- 8Regulatory
- 9Clinical batch
It is a hand-off system, not an event
Each workshop creates the inputs, evidence and questions required by the next stage. That is what makes it repeatable, and what makes the output fundable rather than commemorative.
Display selected epitopes on self-assembling nanoparticles
Regional surveillance sequence data, clinical experience and convalescent sera define the candidates. The platform makes a physical antigen. The laboratory produces gels, ELISA, purification and analytical results. The panel decides what advances.
- Real-world inputs
- Regional surveillance data and convalescent sera
- Laboratory evidence
- Gels, ELISA, purification, analytics
- Development principle
- Use regional data; make and test a physical candidate
- Commercialisable output
- Vaccine and rapid-diagnostic concepts
Infrastructure that already exists
The AdCEV expression platform uses eggs as miniature production units: a rapid, scalable and accessible route to candidate biological products using established laboratory methods.
Eggs are sourced regionally. Technology and people travel from within the region. The output is a proof of concept that can move toward development and commercialisation, produced under real-world, resource-limited, active-outbreak conditions.
Turning African science into regional readiness.
Governments commit to a real product development programme. Partners fund work packages. Participants earn a credential by producing evidence.